Hyperhomocysteinemia recurrence in levodopa-treated Parkinson's disease patients

Eur J Neurol. 2010 May;17(5):661-5. doi: 10.1111/j.1468-1331.2009.02894.x. Epub 2009 Dec 27.

Abstract

Background: Patients with Parkinson's disease (PD) and chronically treated with L-DOPA exhibit, in a percentage of 10-30%, supra-physiological levels of plasma total homocysteinemia (tHcy). In this study, we have investigated, in a group of hyper-homocysteinemic PD patients, the time of hyper-tHcy recurrence after discontinuation of 1-month folate supplementation given to normalize plasma tHcy levels.

Methods: Plasma tHcy, cobalamin and folate were assayed before and after 1-month folate supplementation (5 mg/day), and after 2 and 4 months after folate discontinuation in 29 PD patients (16M/13F, mean age 69.4 +/- 6.9 years) stabilized on a mean L-DOPA dose of 509.4 +/- 312.1 mg/day.

Results: After folate supplementation, plasma tHcy levels fell within the normal range in all patients. At the 2-month control after folate discontinuation, plasma tHcy remained within physiological values in 25 out of 29 patients. Conversely, 4 months after folate discontinuation, all patients exhibited hyper-tHcy.

Conclusions: One-month intake of 5 mg/day folate normalizes plasma tHcy levels in all hyper-homocysteinemic PD patients. Following folate discontinuation, hyper-tHcy recurs in all patients within 4 months. Knowledge of this time interval is useful to optimize pulses of folate therapy in hyper-homocysteinemic patients with PD.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Cross-Sectional Studies
  • Dopamine Agents / adverse effects
  • Dopamine Agents / therapeutic use
  • Female
  • Genetic Predisposition to Disease / genetics
  • Homocysteine / biosynthesis
  • Homocysteine / blood
  • Humans
  • Hyperhomocysteinemia / chemically induced*
  • Hyperhomocysteinemia / drug therapy*
  • Hyperhomocysteinemia / physiopathology
  • Levodopa / adverse effects*
  • Levodopa / therapeutic use
  • Male
  • Middle Aged
  • Parkinson Disease / complications*
  • Parkinson Disease / drug therapy*
  • Parkinson Disease / genetics
  • Prospective Studies
  • Secondary Prevention
  • Treatment Outcome
  • Vitamin B 12 / blood

Substances

  • Dopamine Agents
  • Homocysteine
  • Levodopa
  • Vitamin B 12